Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
|Videos|February 17, 2016
- Gastrointestinal Cancers: mCRC (Issue 7)
- Volume 1
- Issue 7
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
Author(s)Jonathan R. Strosberg, MD
The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Advertisement
Jonathan R. Strosberg, MD, medical oncologist, Moffitt Cancer Center, discusses the results of the phase III NETTER-1 trial. The trial looked at radionuclide therapy Lu-Dotatate (177Lutetium DOTATATE; Lutathera) in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Articles in this issue
over 10 years ago
Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancerover 10 years ago
ERCC1 Expression Falls Short as Chemo Biomarker in mCRCover 10 years ago
Panitumumab Boosts Overall Survival in Chemorefractory mCRCover 10 years ago
Two Options Allows for Treatment Tailoring in Refractory CRCover 10 years ago
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRCAdvertisement
Related to this article
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
New 177Lu-dotatate radioligand therapy expands options for SSTR+ GEP-NETs, backed by NETTER-1 efficacy and key safety guidance.
The FDA has recommended conducting a new trial showing an OS benefit with tovecimig in biliary cancer before submitting a BLA.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5